We publish regularly and promise we won't share your email address with anyone. (Privacy Policy)
SMALL BIZ INFO & RESOURCES
BLOGS TO READ DAILY*
* Don’t have time to read several dozen blogs a day? Pick two or three. Your brain will thank you for it.
ONLINE COMMUNITIES
BLOG DIRECTORIES
THE BUZZ
SPECIAL RESOURCES
Small Business Trends Radio Tuesdays, 1:00 PM Eastern U.S. time on Voice America network
Click to listen
November 1st: Torsten Jacobi, CEO of Creative Weblogging, joins host Anita Campbell. Sponsored by Six Disciplines. Show details.
Sunday, December 21, 2003
Biotech Startups Not Getting SBIR Grants
Biotech industry organizations are lobbying the U.S. Small Business Administration to loosen up its interpretation of Small Business Innovation Research (SBIR) grant rules.
The rules say grants can only be awarded to businesses that are 51 percent or more owned by one individual or individuals who are American citizens. This precludes many biotech firms whose majority owners are venture capital firms from receiving SBIR grants.
The biotech organizations claim the SBA recently became stricter in its interpretation. The SBA says the rules are 21 years old and nothing has changed. However, SBA officials admit that in the past some grants were improperly awarded due to "misunderstanding" of the rules.
Read more about biotech's flap over SBIR grants here and here.
Some of the most promising biotech firms, especially biopharmaceutical firms developing new drugs, are backed by venture capital. That's because the cost of completing product development and clinical trials is expensive. Institutional venture funding is often times the only way these companies can get off the ground and make it through to successful FDA approval. But if the SBA sticks to its strict interpretation of the rules, there won't be any SBIR grants for startups whose ownership is primarily in the hands of venture capital interests. This may limit the benefits of the SBIR grant program for biotechs and particularly biopharms.